Loading...
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) (e.g. gefitinib) currently remain the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) with activating EGFR mutation. However, acquired resistance to gefitinib, which occurs freque...
Saved in:
| Published in: | BMC Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6905032/ https://ncbi.nlm.nih.gov/pubmed/31823748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6416-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|